@article{353e4993f9864f2ca02f52f2e57e9710,
title = "Instability of sputum molecular phenotypes in U-BIOPRED severe asthma",
author = "Kermani, \{Nazanin Z.\} and Stelios Pavlidis and Jiaxing Xie and Kai Sun and Matthew Loza and Fred Baribaud and Fowler, \{Steve J.\} and Shaw, \{Dominic E.\} and Fleming, \{Louise J.\} and Howarth, \{Peter H.\} and Sousa, \{Ana R.\} and Julie Corfield and Charles Auffray and \{De Meulder\}, Bertrand and Sterk, \{Peter J.\} and Yi-Ke Guo and Mohib Uddin and Ratko Djukanovic and Adcock, \{Ian M.\} and Chung, \{Kian Fan\}",
note = "Funding Information: Conflict of interest: N.Z. Kermani has nothing to disclose. S. Pavlidis has nothing to disclose. J. Xie has nothing to disclose. K. Sun has nothing to disclose. M. Loza is an employee and shareholder of Janssen R\&D, Pharmaceutical Companies of Johnson \& Johnson. F. Baribaud is an employee and shareholder of Janssen R\&D, Pharmaceutical Companies of Johnson \& Johnson. S.J. Fowler reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study; personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Novartis, outside the submitted work. D.E. Shaw reports personal fees from GSK, AstraZeneca, Teva and Boehringer Ingelheim, outside the submitted work. L.J. Fleming reports personal fees for advisory board membership from Novartis, Vectura and Boehringer Ingelheim; grants for research from Asthma UK and BLF; personal fees for lectures from Novartis, outside the submitted work. P.H. Howarth reports part time employment by GSK as Global Medical Expert. A.R. Sousa has nothing to disclose. J. Corfield has nothing to disclose. C. Auffray has nothing to disclose. B. De Muelder has nothing to disclose. P.J. Sterk reports grants from Innovative Medicines Initiative (IMI), during the conduct of the study. Y. Guo has nothing to disclose. M. Uddin is an employee of AstraZeneca and holds shares in the company. R. Djukanovic reports personal fees from TEVA, grants and personal fees from Novartis, and personal fees and other support from Synairgen outside the submitted work. I.M. Adcock reports personal fees for advisory board membership from GSK, AstraZeneca, Novartis, Boehringer Ingelehim and Vectura; grants from Pfizer, GSK, MRC, EU, Boehringer Ingelheim and Innovative Medicines Initiative (IMI); and personal fees for lectures, outside the submitted work. K.F. Chung has received honoraria for participating on advisory board meetings of GSK, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Roche and TEVA regarding treatments for asthma and COPD and on the scientific advisory board of the Clean Breathing Institute supported by GSK Health Care Consumer Products; and has also been remunerated for speaking engagements by AstraZeneca, Novartis and Merck, outside the submitted work. Funding Information: Support statement: The U-BIOPRED project is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement 115010, resources of which are composed of financial contributions from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations companies{\textquoteright} in-kind contributions (www.imi.europa.eu). Funding information for this article has been deposited with the Crossref Funder Registry.",
year = "2021",
month = feb,
day = "1",
doi = "10.1183/13993003.01836-2020",
language = "English",
volume = "57",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",
}
SDG 3 Good Health and Well-being